Drugs / SITAFLOXACIN ANHYDROUS
SITAFLOXACIN ANHYDROUS
also known as
Sitafloxacin · DU-6859 · DU-6859A · Sitafloxacin hydrate · Sitafloxacin monohydrate · Sitafloxacin sesquihydrate · Sitafloxacine · Sitafloxacino
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06809413 | Jan → May 2025 overdue | mycobacterial infectious disease | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT02537847 | Nov 2012 → Sep 2015 | acute pyelonephritis, escherichia coli infection | Mahidol University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02729116 | Jul 2016 → Dec 2023 | Klebsiella infectious disease, escherichia coli infection, urinary tract infection | Khon Kaen University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07076225 | Jul 2025 → Jan 2030 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06905522 | Jun 2025 → Jan 2029 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05454345 | Oct 2022 → Jun 2025 | pulmonary tuberculosis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05400369 | Aug 2022 → Sep 2024 | chronic obstructive pulmonary disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT05313750 | Jun 2021 → Dec 2023 | bronchiectasis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-01-28 | Daiichi Sankyo | Regulatory Broad-spectrum Oral Antibacterial Agent Gracevit(R) tablets 50mg/fine granules 10% Receives Approval for Manufacturing and Marketing daiichisankyo.com ↗
DAIICHI SANKYO COMPANY, LIMITED (hereafter; DAIICHI SANKYO) announced it received approval on January 25 for its broad-spectrum antibacterial agent Gracevit(R) (generic name: sitafloxacin hydrate) from the Japanese Ministry of Health, Labour and Welfare. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-01-28 | Daiichi Sankyo | Broad-spectrum Oral Antibacterial Agent Gracevit(R) tablets 50mg/fine granules 10% Receives Approval for Manufacturing and Marketing daiichisankyo.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SITAFLOXACIN ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | DU-6859 | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | DU-6859A | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | Sitafloxacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06809413 ↗ |
| Known as | Sitafloxacin hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | Sitafloxacin monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | Sitafloxacin sesquihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | Sitafloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Known as | Sitafloxacino | ChEMBL registry synonym — accepted as the source's own label CHEMBL108821 ↗ |
| Modality | Small molecule | — CHEMBL108821 ↗ |
| Route | Oral | “oral sitafloxacin (100 mg twice daily)” NCT02537847 ↗ |